Cancer care predictions 2020: The best is yet to come
January 7, 2020 | By Abe Rosenberg
City of Hope clinicians and researchers are brimming with optimism as 2020 begins. Cancer care is changing rapidly, and the pace of change is accelerating. In 2020 look for major advances in gene-based therapy, immunotherapy and many other areas.
Two new deans, David Ann, Ph.D., and Yilun Liu, Ph.D., have taken the helm of City of Hope’s graduate program, determined to attract the best and brightest students from around the nation and the globe.
Results from a study by City of Hope researchers show that patients who underwent a stem cell transplant and received the Triplex vaccine to prevent cytomegalovirus infection were 50% less likely to develop health complications related to the virus than others.
Say the words “brain tumor” and most people will likely think of cancer.
But there’s reason for optimism - recent advances in screening and treatment, such as CAR T cell therapy, mean patient outcomes and quality of life are continuing to improve.
In the past seven years at City of Hope, I’ve had the privilege of providing care for many patients with cancer. Quite simply, they are the real superhumans. Please allow me to offer four examples for your consideration, from my personal insight.
January 13, 2016 | by
Vijay Trisal, M.D., F.A.C.S.
We have made tangible advances in technology and have a better understanding of the molecular mechanisms of the drivers of cancer. This has advanced our ability to interrupt the growth of cancer. However, we need to take a step back and seriously examine the social and psychological harm that the disease can cause.
Brain cancer is one of the toughest foes a doctor can face. It’s a tenacious form of cancer, inoperable in some cases and lethal in many. But at City of Hope, researchers are exploring new ways to conquer the most serious types of brain tumors in a clinical trial that deploys a patient’s own modified T cells to target cancer at the tumor site.
As an editor for more than 20 years, Erin Michaela Sweeney was adept at helping people find the right words to express themselves. But after five rounds of chemotherapy, she found herself using the imprecise word “thingy” in sentences to refer to objects whose name she couldn’t remember.
Stat, Myc, Myb, Fos, Ras, and Fox: Those bland monosyllables, unfamiliar to most of us, command the respect and fear of oncologists and cancer researchers worldwide. Why? Because they name proteins that drive uncontrollable cell division, metastasis, and/or drug resistance in numerous cancers.